PPARγ ligands are known to inhibit or repress the activity of a number of transcription factors important in innate immunity, inflammation and cancer, including Stat3 and NF-κB [158, 159]; therefore, targeted inhibition of Stat3 and NF-κB activity with PPARγ agonists is a relevant avenue of investigation for new cancer therapeutics [213]. This evidence concerns the gene STAT3 and cancer.